Emergent BioSolutions (STU:ER4) Total Receivables: €105.2 Mil (As of Mar. 2026)


STU:ER4 Emergent BioSolutions Inc STU:ER4
57 GF Score
Price €7.01
GF Value €4.11
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Total Receivables?

Emergent BioSolutions STU:ER4 -0.85% 57 Total Receivables is €105.2 Mil as of Mar. 2026. GuruFocus rates STU:ER4 with a GF Score™ of 57/100 and a GF Value™ of €4.11 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Emergent BioSolutions's Total Receivables for the quarter that ended in Mar. 2026 was €105.2 Mil.

Emergent BioSolutions Total Receivables Related Terms

Emergent BioSolutions Total Receivables Historical Data

* Premium members only.

The historical data trend for Emergent BioSolutions's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions Total Receivables Chart

Emergent BioSolutions Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 246.83 150.29 175.15 147.55 71.91

Emergent BioSolutions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 188.42 69.19 127.37 71.91 105.18
STU:ER4
57GF Score
Emergent BioSolutions Inc STU:ER4
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Emergent BioSolutions Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €105.2 Mil mean?
Emergent BioSolutions (STU:ER4) has a Total Receivables of €105.2 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Emergent BioSolutions and its competitors.
Is Emergent BioSolutions' Total Receivables too high?
Emergent BioSolutions' current Total Receivables is €105.2 Mil. Overall, Emergent BioSolutions has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Total Receivables compare to ELTP and NIKA?
Emergent BioSolutions' Total Receivables of €105.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Emergent BioSolutions and its competitors. Emergent BioSolutions's current Total Receivables is €105.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.11, compared to a current price of €7.01 — trading 70.6% above its estimated fair value. The current Total Receivables is €105.2 Mil. Emergent BioSolutions' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Total Receivables is €105.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €7.01 is trading 70.6% above its estimated GF Value™ of €4.11. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for STU:ER4:

  • Total Receivables: €105.2 Mil
  • GF Value™: €4.11 vs. price of €7.01 (70.6% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UK
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
57GF Score

Get the complete analysis for STU:ER4

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.01
Price
€4.11
GF Value